{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4142","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Response"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"title":"Non-response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Alkaline Phosphatase response (Response or Non-Response \\[Stable, Progression\\]) from baseline through 12 months of treatment in subjects with hepatic involvement","groups":[{"description":"NEOD001, 24 mg/kg IV every 4 weeks for 12 months","id":"OG000","title":"NEOD001 24 mg/kg"},{"description":"Placebo, 0.9% Saline IV every 4 weeks for 12 months","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Hepatic Evaluable Population","reportingStatus":"POSTED","timeFrame":"Baseline through 12 months of treatment","title":"Hepatic Best Response","type":"SECONDARY","unitOfMeasure":"Participants"}